例如:"NBL1", "4681", "drought"
收藏
28987 NOB1

28987

NOB1

NIN1 (RPN12) binding protein 1 homolog

protein-coding

Homo sapiens

基因描述

Type Description
Definition NIN1 (RPN12) binding protein 1 homolog

研究结论

Date Results Publications
2021-01-23 12:58:00 MiR-363 suppresses cell migration, invasion, and epithelial-mesenchymal transition of osteosarcoma by binding to NOB1. 32357945
2020-09-19 16:29:00 MicroRNA-139-3p suppresses growth and metastasis of glioblastoma via inhibition of NIN1/RPNI2 binding protein 1 homolog. 31173298
2020-08-22 15:26:00 NOB1: A Potential Biomarker or Target in Cancer. 30854959
2019-09-21 12:18:00 NOB1 was correlated with clinical outcomes and prognosis of gastric cancer patients and was an independent risk factor for 5-year mortality of GC patients. 30274015
2019-06-01 10:22:00 miR744 may inhibit the progression of papillary throid cancer by directly targeting NOB1. 30628685

名称对应

Type IDs
Synonymous ART-4, MST158, MSTP158, NOB1P, PSMD8BP1
Gene
UniProtKB-ID: NOB1_HUMAN
UniprotKB: Q9ULX3
UniParc: UPI0000034E10
EMBL: AB026125, AF190161, BC064630, AY487344, BC000050, AK001028
Ensembl: ENSG00000141101
KO: hsa:28987
Nucleutide sequences
EMBL-CDS: AAR85357.1, BAA91473.1, AAH00050.2, AAH64630.1, BAA86961.1, AAQ13705.1
Gene_ORFName: MSTP158
Ensembl_TRS: ENST00000268802
Protein sequencees
Ensembl_PRO: ENSP00000268802
RefSeq: NP_054781.1
Others
UniRef100: UniRef100_Q9ULX3
UniRef90: UniRef90_Q9ULX3
UniRef50: UniRef50_Q9ULX3
UniGene: Hs.271695
CCDS: CCDS10884.1

全选

{{proteinIndex+1}}
mRNA Protein UniprotKB Description
Refseq {{protein.nucleotideVersion}}

Ensembl: {{protein.nucleotideEnsembl}}

{{protein.proteinVersion}}

Ensembl: {{protein.proteinEnsembl}}

{{uniprot}}
Definition: {{{protein.definition}}}

Transcript Veriant:{{protein.transcriptVeriant}}

Status: {{protein.status}}

Location ( {{protein.positionStart}}..{{protein.positionEnd}} )

暂无数据

研究热度

热点单位
排名 科研单位 文献
{{affIndex+1}}

{{aff.value}}

{{aff.size}}

目前还没有研究热点单位

热点人员
排名 研究人员 文献
{{authorIndex+1}}

{{author.value}}

{{author.size}}

目前还没有研究热点人员